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AIMS: Despite their low levels of ectopic fat accumulation, populations of African ancestry 32 
exhibit hyperinsulinaemia and increased metabolic risk.  We aimed to investigate relationships 33 
between insulin clearance, insulin secretion, hepatic fat accumulation and insulin sensitivity in 34 
black African (BA) and white European (WE) men. 35 
METHODS: 23 BA and 23 WE men with normal glucose tolerance, matched for age and body 36 
mass index, underwent a hyperglycaemic clamp to measure insulin secretion and clearance; 37 
hyperinsulinaemic-euglycaemic clamp with stable glucose isotope infusion to measure whole-38 
body and hepatic-specific insulin sensitivity; and magnetic resonance imaging to quantify 39 
intrahepatic lipid (IHL). 40 
RESULTS: BA men had higher glucose-stimulated peripheral insulin levels (48.1 (35.5, 65.2) 41 
x 103 vs 29.9 (23.3, 38.4) x103 pmol L-1 x min, p=0.017) and lower endogeneous insulin 42 
clearance (771.6 (227.8) vs 1381 (534.3) mL m-2 BSA min -1, p<0.001) compared with WE 43 
men.  There were no ethnic differences in beta cell insulin secretion or beta cell responsivity 44 
to glucose, even after adjustment for prevailing insulin sensitivity.  In WE men, endogenous 45 
insulin clearance was correlated with whole-body insulin sensitivity (r=0.691, p=0.001) and 46 
inversely correlated with IHL (r= -0.674, p=0.001). These associations were not found in BA 47 
men.   48 
CONCLUSIONS: While normally glucose tolerant BA men have similar insulin secretory 49 
responses to their WE counterparts, they have markedly lower insulin clearance, which does 50 
not appear to be explained by either insulin resistance or hepatic fat accumulation.   Low insulin 51 
clearance may be the primary mechanism of hyperinsulinaemia in populations of African 52 
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The multifaceted pathophysiology of type 2 diabetes (T2D) includes peripheral and hepatic 70 
insulin resistance, reduced insulin clearance and beta-cell dysfunction. Insulin secreted by the 71 
pancreatic beta cell is delivered directly via the portal vein to the liver, where the majority of 72 
endogenous insulin clearance occurs [1]. The predominant mechanism of hepatic insulin 73 
clearance involves insulin binding to its receptor on the hepatocyte surface, with endocytosis 74 
and internalisation of the insulin-receptor complex and subsequent degradation [2]. Therefore, 75 
hepatic insulin clearance is an integral part of insulin’s action on the liver, with greater hepatic 76 
insulin sensitivity associated with greater clearance [3].  Intrahepatic lipid (IHL) plays a key 77 
role in glucose/insulin dysregulation; while the mechanisms are not fully understood, the 78 
accumulation of lipotoxic mediators has been found to inhibit insulin receptor activation [4].  79 
In this way, accumulation of IHL is believed to drive impairments in both insulin clearance 80 
and hepatic insulin sensitivity  [5-8].  81 
 82 
Populations of black African (BA) ethnicity suffer a disproportionately elevated risk of T2D 83 
[9, 10], yet they are relatively protected from ectopic fat deposition and exhibit lower IHL 84 
relative to other ethnicities (the so-called “African paradox”) [11]. Distinctive features of 85 
insulin dynamics are well-documented in populations of African ethnicity [12], with an 86 
exaggerated insulin response to glucose in BA subjects demonstrated across a spectrum of 87 
glucose tolerance [13-17].  An important contributor to this phenomenon is the relatively low 88 
insulin clearance of BA populations, which has been consistently recognised [18-22]. 89 
Reductions in insulin clearance appear to be a predictor of T2D in this ethnic group [23] and 90 





We have previously shown that fasting hepatic insulin resistance in BA men with early T2D 92 
appears to be independent of IHL [25] and that there are ethnic differences in the relationship 93 
between ectopic fat accumulation and insulin sensitivity [26].  This has led us to hypothesise 94 
that the role of IHL in insulin clearance may differ by ethnicity. To our knowledge, this is the 95 
first study to examine the impact of BA ethnicity on relationships between insulin clearance, 96 






Study Design 99 
The data were collected as part of “Soul-Deep II”, a cross-sectional study of the development 100 
of type 2 diabetes in men resident in South London from two ethnic groups, white European 101 
(WE) and black (West) African (BA).  Metabolic assessments were performed at the Clinical 102 
Research Facility, King’s College Hospital, London, UK, while MRI imaging took place at 103 
Guy’s Hospital, London, UK.  The study was approved by the London Bridge National 104 
Research Ethics Committee (15/LO/1121). Recruitment of subjects and data collection took 105 
place between April 2016 and May 2018.  Recruitment was carried out through advertising in 106 
the local press and via South London primary care practices. All subjects provided written 107 
informed consent prior to the study. 108 
 109 
Subjects 110 
Eligible subjects were male, aged 18-65 years, of either white European (WE) or black (West) 111 
African (BA) ethnicity.  Ethnicity was self-declared and confirmed by grandparental 112 
birthplace.  Eligible WE subjects had 4 WE grandparents with at least two of these from North 113 
West European countries as defined by the United Nations Statistics Division (UNSD) [27]. 114 
Eligible BA subjects had 4 BA grandparents from West African countries as defined by UNSD.  115 
 116 
Subjects were invited to a screening assessment at the Clinical Research Facility at King’s 117 
College Hospital, following a 10 hour fast, in order to undertake a screening questionnaire, 118 
anthropometric measurements and a 2 hour, 75g oral glucose tolerance test (OGTT).  Eligible 119 






Exclusion criteria were: a diagnosis of diabetes; treatment with oral hypoglycaemic agents, 122 
insulin, systemic steroids or beta blockers; any condition or medication considered by the 123 
investigators to have substantial impact on the study protocol or outcomes; serum creatinine of 124 
>150 µmol/l; serum alanine transaminase level >2.5 fold above the upper limit of the reference 125 
range; sickle cell disease (trait permitted).  Participants were instructed to refrain from 1) 126 
strenuous physical activity for 48-hours 2) alcohol consumption for 24-hours and 3) food and 127 
drink (other than water) for at least 10 hours prior to the study visits.  128 
 129 
Hyperglycaemic clamp assessment of first- and second- phase insulin secretory function 130 
and insulin clearance 131 
Following an overnight fast, participants were admitted to the Clinical Research Facility and 132 
weighed in light clothing.  A cannula was inserted into the antecubital fossa vein of the non-133 
dominant arm for administration of the glucose infusion and a second cannula inserted 134 
retrogradely into the dorsum of the contralateral hand for blood sampling.  The sampling hand 135 
was placed in a hand-warming unit at 55 ⁰C in order to achieve arterialised venous blood.  A 136 
primed, variable rate intravenous infusion of 20% (wt/vol) dextrose was administered for 120 137 
minutes to achieve square-wave hyperglycaemia with a plasma glucose concentration of 6.9 138 
mmol/L above baseline, according to the protocol of DeFronzo et al [29].  Glucose, insulin, 139 
and C-peptide concentrations were measured at fasting (-20, -10, 0 minutes) and at 2, 4, 6, 8, 140 
10, 15, 20, 30, 40, 50, 60, 75, 90, 105, and 120 minutes.  141 
 142 
Hyperinsulinaemic-euglycaemic clamp assessment of insulin sensitivity 143 
The full methodology has been described [26].  In brief, a two-step hyperinsulinaemic–144 
euglycaemic clamp with a stable glucose isotope infusion was used to assess whole-body and 145 
hepatic-specific insulin sensitivity. Participants were admitted to the Clinical Research Facility 146 





(2.0 mg/kg), continuous infusion (0.02 mg kg−1 min−1) of [6,6 2H2]-glucose (CK Gases, 148 
Cambridgeshire, UK) was initiated at -120 minutes. Blood samples were taken at -30, -20, -10 149 
and 0 minutes for basal assessments. The clamp began at 0 minutes with a primed continuous 150 
insulin infusion (Actrapid, Novo Nordisk, Bagsvaerd, Denmark) bound to albumin at a rate of 151 
10 mU m−2 BSA min−1 for 2 hours (low dose insulin phase) for assessment of hepatic insulin 152 
sensitivity. For the final 2 hours, the insulin infusion rate was re-primed and increased to 40 153 
mU m−2 BSA min−1 (high dose insulin phase) for assessment of whole-body insulin sensitivity.  154 
Euglycaemia (5.0 mmol/l) was achieved using variable rate 20% (wt/vol) dextrose enriched 155 
with [6,6 2H2]-glucose (8 mg/g glucose) to maintain a constant tracer-to-tracee ratio. Blood 156 
was drawn at 30, 60, 90, 100, 110, 120, 150, 180, 210, 220, 230 and 240 minutes for the 157 
assessment of plasma glucose concentration, isotopic enrichment and insulin concentration.  158 
 159 
Magnetic Resonance Imaging assessment of IHL  160 
The full imaging protocol has been reported [30]. In brief, a Dixon-based MRI sequence was 161 
used on a 1.5 Tesla Siemens scanner to obtain images from the neck to the knee (excluding 162 
arms).  384 contiguous, axial T1-weighted gradient-echo images with a slice thickness of 3mm 163 
were acquired, from which fat and water images were produced as part of the Dixon sequence. 164 
MRI data were analysed using the open source image analysis software HOROS V 1.1.7 165 
(www.horosproject.org; accessed 21/10/2017) by a single, blinded analyst (OH).   166 
In each participant, two abdominal MRI images approximately 30mm apart were selected, 167 
representing the superior and inferior sections of the liver. In each pair of water and fat MRI 168 
images, 4 circular regions of interest (ROIs) in identical positions were placed within the liver 169 
tissue. The hepatic fat fraction (HFF) was quantified in each ROI by using the formula %HFF 170 
= (F/(F+W)) *100 where F is the pixel signal intensity of the fat image and W is the pixel signal 171 





Biochemical analyses 173 
Plasma glucose concentrations were determined at the bedside using an automated glucose 174 
analyser (Yellow Spring Instruments, 2300 STAT Glucose Analyzer, Ohio, USA). Plasma 175 
insulin concentrations were determined by immunoassay using chemiluminescent technology 176 
(ADVIA Centaur System, Siemens Healthcare Ltd. Camberly, UK). Plasma C-peptide 177 
concentrations were determined by radioimmunoassay (Millipore Ltd, Hertfordshire, UK). 178 
Plasma glucose isotope enrichments were measured by gas chromatography-mass 179 
spectrometry on an Agilent GCMS 5975C MSD (Agilent Technologies, Wokingham, UK).  180 
 181 
Calculations 182 
Whole-body insulin sensitivity was quantified using the M value (mg/kg FFM min−1) measured 183 
during the final 30 min of the high-dose insulin phase of the clamp, calculated as total glucose 184 
disposal corrected for deviations in plasma glucose concentration [26]. Whole-body insulin 185 
sensitivity was also expressed as M/I, the M value corrected for the steady state insulin 186 
concentration during the last 30 minutes of the clamp (mg kg -1 FFM min−1)/ (pmol L-1). 187 
 188 
Steele’s non-steady-state equations, modified for stable isotopes, were used to determine total 189 
glucose rate of appearance, Ra (μmol kg -1 FFM min-1) [31].  Endogenous glucose production 190 
(EGP) was calculated by subtracting exogenous glucose infusion rate from total glucose Ra.  191 
Hepatic insulin sensitivity was expressed as the percentage suppression of EGP from basal to 192 
the final 30 minutes of the clamp (% suppression of EGP).  193 
 194 
The clearance rate of the exogenously administered insulin infusion during the 195 





calculated as the insulin infusion rate divided by the insulin concentration during the steady 197 
state period in the final 30 minutes of the clamp (mL m-2 BSA min -1). 198 
 199 
The incremental areas under the curve (iAUC) were calculated using the trapezoid rule for C-200 
peptide, insulin and glucose.  Classical indices of first- and second-phase insulin secretion 201 
during the hyperglycaemic clamp were determined by calculating the iAUC for C-peptide for 202 
0 to 10 minutes and 10 to 120 minutes respectively.    203 
 204 
Parameters of beta cell function were obtained by modelling the glucose and C-peptide curves 205 
during the hyperglycaemic clamp using published methods [32, 33]. Model assessments were 206 
carried out using SAAM-II 1.2 software (SAAM Institute, Seattle, Washington). The main 207 
outputs of the model are: pre-hepatic endogenous insulin secretion (expressed as area under 208 
the curve of insulin secretion rate over 120 minutes, AUCISR); beta cell glucose sensitivity of 209 
first-phase secretion (σ1), expressed as the amount of insulin secreted in response to a rate of 210 
increase in glucose of 1 mmol/L between time 0 and 1 minute of the study, in (pmol m-2 211 
BSA)/(mmol L-1 min-1), beta cell glucose sensitivity of second-phase secretion (σ2), expressed 212 
as the steady-state insulin secretion rate in response to a step increase in glucose of 1 mmol/L 213 
above baseline, in (pmol min-1  m2)/(mmol L-1).  214 
 215 
During the hyperglycaemic clamp, average (endogenous) insulin clearance was calculated 216 
according to the following formula [33]: 217 
 218 
where AUCISR is the area under the curve of insulin secretion rate, AUCI is the area under the 219 





insulin concentration at the beginning of the study, and MRTIns is the mean residence time of 221 
insulin, which was assumed to be 18 minutes as reported in Navalesi et al [34]. 222 
 223 
Statistical analysis 224 
Log-transformation was used on skewed variables that showed a significant deviation from 225 
normality to achieve a normal distribution prior to the use of parametric tests. Data are 226 
expressed as means (SD) for non-transformed data and geometric mean (95% confidence 227 
intervals) for log-transformed data.  Significance of differences in variables between the two 228 
ethnic groups were made using independent sample Student’s t test. The strength of 229 
associations between variables of interest was assessed using Pearson’s correlation. The ethnic 230 
differences in relationships between endogenous insulin clearance and whole-body insulin 231 
sensitivity, hepatic insulin sensitivity, intrahepatic lipid and MCRI, were examined by fitting 232 
a regression model between the pairs of variables with an interaction term for ethnicity. Prior 233 
to running the regression models, collinearity diagnostics were performed for the whole cohort 234 
for insulin clearance with ethnicity, hepatic fat (IHL), insulin sensitivity (M value) and insulin 235 
secretion (AUC_ISR).  The VIFs for these factors were used to exclude multicollinearity. An 236 
ANCOVA was used, with insulin secretion (AUCISR), intrahepatic lipid (IHL), hepatic insulin 237 
sensitivity (% suppression of EGP) and whole-body insulin sensitivity (M value) as co-variates, 238 
to investigate ethnic differences in average endogenous insulin clearance.  An ANCOVA was 239 
used with whole-body insulin sensitivity (M value) as a co-variate, to investigate ethnic 240 
differences in endogenous insulin secretion.  Missing data were excluded pairwise for all 241 
analyses; in the case of the correlation analysis between IHL and insulin clearance, this led to 242 
skewing of the IHL data which was therefore log-transformed for this analysis. All analyses 243 








Participant characteristics 248 
The characteristics of the 23 BA and 23 WE men are presented in Table 1. The two ethnic 249 
groups were well-matched for age, weight and BMI and showed no difference in HbA1c, blood 250 
pressure or fasting glucose (Table 1). The BA men had significantly lower fasting triglyceride 251 
levels (Table 1). 252 
 253 
Beta cell insulin secretory function 254 
There were no ethnic differences in fasting C-peptide or fasting insulin (Table 2).  By design, 255 
there was no difference in “clamped” glucose during the hyperglycaemic clamp (BA= 12.1 256 
(0.65) vs WE = 12.0 (0.63) mmol/L, p= 0.635).  257 
 258 
Mean peripheral insulin levels were approximately 1.5-fold higher during both first and second 259 
phase of the hyperglycaemic clamp in BA compared with WE men (Figure 1a), while there 260 
were no ethnic differences in C-peptide response (Table 2, Figure 1b), endogenous beta cell 261 
insulin secretion (AUCISR) (Table 2) or sensitivity of the beta cell to glucose during first or 262 
second phase insulin secretion, σ1 and σ2 (Table 2). This remained the case after measures of 263 
beta cell insulin secretion were adjusted for whole-body insulin sensitivity (p = 0.512). 264 
 265 
Intrahepatic lipid and insulin sensitivity 266 
Data on IHL, whole body and hepatic insulin sensitivity, as previously reported by our group 267 
[26, 30] showed IHL was lower in BA men, while there were no ethnic differences in hepatic 268 
insulin sensitivity or whole-body insulin sensitivity by either M value or M/I (included in Table 269 






Insulin clearance 272 
 273 
Average endogenous insulin clearance was almost 50% lower in BA compared with WE men 274 
during the hyperglycaemic clamp (Table 2).  The ethnic difference remained significant after 275 
adjusting for whole-body insulin sensitivity (M value), endogenous insulin secretion (AUCISR), 276 
intrahepatic lipid (IHL) and hepatic insulin sensitivity (% suppression of EGP) (p < 0.001). 277 
Clearance of exogenous insulin as determined by MCRI was also lower in BA compared with 278 
WE men (Table 2). 279 
 280 
Relationships between endogenous insulin clearance and intrahepatic lipid, insulin 281 
sensitivity and insulin secretion  282 
 283 
In WE men, endogenous insulin clearance was correlated with whole-body (Figure 2a & 2b) 284 
and hepatic insulin sensitivity (Figure 2c) and with MCRI (Figure 2d), while it was inversely 285 
correlated with IHL (Figure 2e).  These relationships were not found in the BA men (figure 2 286 
a-e).   287 
 288 
In multiple regression analysis, an ethnicity interaction was found in the relationship between 289 
endogenous insulin clearance and whole-body insulin sensitivity (Figure 2a; p-interaction = 290 
0.022). An ethnicity interaction was also found in the relationship between the measurements 291 
of endogenous insulin clearance and MCRI (Figure 2d; p-interaction = 0.021).  A trend was found 292 
for an ethnicity interaction between endogenous insulin clearance and hepatic insulin 293 
sensitivity (Figure 2c; p-interaction=0.057). No ethnicity interaction was found between insulin 294 
clearance and IHL.   295 






This study comprises a comprehensive investigation of insulin clearance and its relationships 298 
with hepatic fat and insulin sensitivity in white European and black African men with normal 299 
glucose tolerance.  To our knowledge, it is the first to demonstrate that the markedly low insulin 300 
clearance of an African origin population may occur in the absence of insulin resistance.  While 301 
the classical paradigm suggests that increased insulin resistance drives the excess diabetes risk 302 
in BA populations, these findings contribute to a newly emerging (and as yet, controversial) 303 
paradigm, which proposes that impairments in insulin clearance are the primary aetiological 304 
mechanism of glucose intolerance in this ethnic group [35, 36].  305 
 306 
In this study, the response to intravenous glucose in the BA men was characterised by a 307 
pronounced hyperinsulinaemia compared with that of the WE men (Figure 1). While this is 308 
well-documented in the literature, it has previously been described as a compensatory response 309 
by the beta cell to increased insulin resistance and/or a consequence of “upregulated” beta cell 310 
function [14, 18, 37-39].  By contrast, in our study population we found that there were no 311 
ethnic differences in total beta cell insulin secretion, corroborating the findings of the Federal 312 
Women’s Study [22] and developing an evidence base which disputes the argument that people 313 
of African ancestry typically exhibit insulin hypersecretion.     314 
 315 
We acknowledge that much of the literature, including the Federal Women’s study [22], report 316 
greater first phase beta cell responsivity in African-ancestry groups [38] whereas we found no 317 
ethnic differences in either first or second phase beta cell responsivity to glucose.  Our results 318 
may differ as this is one of the few studies to comprise exclusively of adult men, rather than 319 
children/adolescents [18, 19, 37, 38, 40] or all-female cohorts [39, 41-45]. Two other adult 320 





neither found increased insulin secretion in the African-ancestry subjects compared with white 322 
subjects, consistent with our findings.  It is worth considering that the paucity of male 323 
participants in this area of the literature may have led to an overestimation of ethnic differences 324 
in insulin secretory response [48].   325 
 326 
We found that the peripheral hyperinsulinaemia of our BA population was due to the ethnic 327 
difference in insulin clearance; furthermore, this difference persisted after adjustment for 328 
insulin sensitivity, hepatic fat content and insulin secretion rate.  Whilst insulin clearance was 329 
associated with IHL and whole body and hepatic insulin sensitivity in WE men, these 330 
associations were absent in the BA men. Insulin clearance is a highly variable process which 331 
operates under the influence of multiple physiological factors.  The predominant cellular 332 
mechanism is receptor-mediated uptake and therefore a correlation is typically seen between 333 
insulin sensitivity and insulin clearance [49, 50].  Our data in the WE men are in keeping with 334 
these expected relationships.  In the BA men, where such relationships are not observed, we 335 
may postulate that such mechanisms operate differently between the ethnic groups, or with 336 
different dose-responses.   337 
 338 
This leads us to propose that endogenous insulin clearance in BA may be determined by 339 
additional factors which are independent of insulin sensitivity, e.g. in the pathways involved in 340 
post-receptor insulin metabolism. This assertion is supported by recent evidence from a study 341 
investigating ethnic differences in the expression and activity of hepatic insulin-degrading 342 
enzyme (IDE) and carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) 343 
between African-Americans and non-Hispanic White Americans, which reported lower IDE 344 
activity in African-Americans [51]. While reduced insulin clearance is widely regarded as an 345 





are not only a compensatory mechanism but also a primary determinant of peripheral insulin 347 
levels [36, 54] in BA populations. 348 
 349 
Low insulin clearance has been demonstrated in African American women [22], in pre-pubertal 350 
African-American children [18, 21, 55], in indigenous adult Ghanaians [56] and, with this 351 
study, in black West African men living in the UK.  The finding of this distinctive physiological 352 
characteristic in diverse populations of African ancestry is suggestive of a genetic rather than 353 
environmentally mediated mechanism.  The strong heritability of insulin clearance has been 354 
demonstrated in a Hispanic population [57] and this may also be the case in other ethnic groups.  355 
Molecular mechanisms that warrant further exploration include potential ethnic differences in 356 
inflammatory activity [24], the expression and activity of insulin-degrading enzyme [51], the 357 
liver-adiponectin pathway [58], or in liver CEACAM-1 expression/activity [2].  358 
 359 
We note that clearance of exogenously administered insulin (as determined by the MCRI) is 360 
also lower in BA compared to WE, although the difference is not as marked as for endogenous 361 
insulin clearance.  This may be expected, because while only endogenously secreted insulin 362 
undergoes first pass hepatic metabolism, exogenously administered insulin also undergoes both 363 
hepatic and extra-hepatic clearance (with around 60% of peripherally administered insulin 364 
thought to be cleared by the liver [59]). 365 
 366 
Importantly, while MCRI is closely correlated with endogenous insulin clearance in WE, this 367 
is not the case in BA and ethnicity has a significant impact on the relationship between the two 368 
measures.  We note that models have shown that while hepatic insulin clearance is lower in 369 
black ethnic groups compared with whites, extra-hepatic clearance is similar [20, 21] and that 370 





clearance contributes in greater proportion to endogenous compared with exogenous insulin 372 
clearance, this may explain why the MCRI does not reflect endogenous insulin clearance in the 373 
black African men.  These finding have implications for the use of MCRI as a measure of 374 
insulin clearance in black ethnic groups.  375 
 376 
The strengths of this study include the well-matched ethnic groups and the use of rigorous, 377 
gold-standard methods of metabolic analysis.  Unlike some previous ethnic comparison studies 378 
[48], the subject groups were tightly characterised; of single sex with metabolic status 379 
confirmed by OGTT. 380 
 381 
In terms of limitations, the study is cross-sectional and is only able to recognise the presence 382 
or absence of associations, between hepatic fat, insulin sensitivity and insulin clearance.  Only 383 
longitudinal measures would be able to determine the true dynamics of these mechanisms and 384 
determine causality. The measure of average endogenous insulin clearance does not enable 385 
differentiation between hepatic and extra-hepatic insulin clearance, although it has been shown 386 
that approximately 80% of endogenous insulin is cleared by the liver [1]. Furthermore, the 387 
influence of gut-modulated insulin secretion and clearance was not assessed. There is evidence 388 
that the incretin hormones reduce post-prandial insulin clearance [61-63] and ethnic differences 389 
in incretin hormones have been recognised [33, 64, 65], albeit the data are inconsistent.  390 
However, it is not clear whether incretins contribute to ethnic differences in insulin clearance, 391 
which would be an important line of enquiry for future investigations. We also acknowledge 392 
that the failure to find an association between IHL and insulin clearance in the BA men does 393 
not mean that an association does not exist. Our sample size is comparable with other studies 394 
in the literature, but we may not be powered to reliably detect such associations. While the 395 





a linear correlation between IHL and insulin clearance, the range in IHL that we observed is 397 
reflective of IHL in black populations, as reported in a large epidemiological study [66] . In 398 
data we have previously reported from an obese diabetic population [25], we did find a trend 399 
to an inverse relationship between insulin clearance and intrahepatic lipid in the BA 400 
participants, suggesting that there may be a threshold mechanism at play and that IHL may not 401 
have a significant role in the determination of insulin clearance until higher levels of 402 
accumulation have occurred.   403 
 404 
The study comprises male subjects only and therefore may not be generalisable to women; 405 
however, as the majority of the work in this area has been carried out in African ancestry 406 
females [48], this cohort offers a valuable addition to the field.   407 
 408 
In conclusion, this study demonstrates low insulin clearance in black African men despite lower 409 
hepatic fat and similar whole-body and hepatic insulin sensitivity to their white European 410 
counterparts. It is increasingly recognised that type 2 diabetes is a heterogenous disease, where 411 
different aetiological components may have an impact on progression rates and choice of 412 
therapeutic strategy [67].  Ethnic disparities in treatment response have already been 413 
recognised [68] and may be explained, at least in part, by inherent physiological variations.  In 414 
healthy black African men, the lack of association of endogenous insulin clearance with either 415 
intrahepatic lipid or insulin sensitivity supports the hypothesis that low insulin clearance is a 416 
primary phenomenon in this ethnic group. Such a phenomenon warrants further exploration, 417 
as it may offer novel therapeutic targets for the treatment and prevention of diabetes.  Both the 418 
determinants of low insulin clearance and its role in the high risk of metabolic dysfunction in 419 
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Figure 1 
a: Plasma insulin response by ethnic group during the hyperglycaemic clamp.  




a: Associations between endogenous insulin clearance and whole-body insulin sensitivity (M 
value). 
b: Associations between endogenous insulin clearance and whole-body insulin sensitivity 
(M/I). 
c: Associations between endogenous insulin clearance and hepatic insulin sensitivity (% 
suppression EGP) 
d: Associations between average endogenous insulin clearance and MCRI 
e. Associations between endogenous insulin clearance and intrahepatic lipid (IHL)  
 





Table 1: Clinical characteristics of study participants.   422 
 423 
 BA (n=23) WE (n=23) p value 
Age (years) 30.7 (12.0) 35.9 (13.9) 0.18 
Weight (kg) 84.1 (14.6) 86.5 (16.5) 0.60 
BMI (kg m-2) 26.7 (3.6) 26.5 (4.6) 0.86 
Waist circumference (cm) 87.5 (9.3) 93.8 (14.6) 0.09 
Fasting glucose (mmol L-1) 5.25 (0.4) 5.20 (0.4) 0.51 
HbA1c IFCC (mmol/mol) 37.0 (5.3) 35.9 (2.9) 0.37 
HbA1c DCCT (%) 5.54 (0.48) 5.44 (0.24) 0.38 
Systolic blood pressure (mmHg) 123.1 (12.3) 121.9 (9.1) 0.70 
Diastolic blood pressure (mmHg) 70.7 (11.5) 71.1 (8.2) 0.88 
LDL-cholesterol (mmol L-1) 2.66 (0.87) 2.99 (0.82) 0.19 
HDL-cholesterol (mmol L-1) 1.30 (0.42) 1.27 (0.31) 0.75 
Total cholesterol (mmol L-1) 4.27 (1.06) 4.76 (1.05) 0.13 
Triglycerides (mmol L-1) 0.68 (0.25) 1.10 (0.56) 0.003 
Data presented as mean (SD).  Differences between the two ethnic groups determined using independent sample 424 
Student’s t test.  Fasting glucose values taken at screening visit. Abbreviations: BA black African; DCCT 425 
Diabetes Control and Complications Trial; HbA1c glycated haemoglobin; HDL high density lipoprotein; IFCC 426 






Table 2:  Metabolic parameters of insulin secretion and insulin clearance  
 
BA (n=23) WE (n=23) Mean difference or 
ratio of geometric 
mean (95% CI)  
p value 
Fasting plasma glucose 
(mmol L-1) 
5.26 (0.35) 5.19 (0.32) -0.07 (-0.28, 0.13) 0.460 




0.54 (0.47, 0.62) 0.61 (0.50, 0.76) 1.14 (0.89, 1.47) 0.281 




46.2 (38.6, 55.3) 39.4 (30.2, 51.6) 0.85 (0.62, 1.17) 0.314 
iAUCc-pep 0-10 mins 
†
 
(nmol L-1 x min) 
8.45 (6.17, 11.6) 6.88 (5.83, 8.3) 0.81 (0.58, 1.15) 0.240 
iAUCc-pep 10-120 mins 
(nmol L-1 x min) 
242.1 (109.9) 213.2 (60.4) -28.9 (-82.0, 24.3) 0.277 
iAUCins 0-10 mins 
†
 
(pmol L-1 x min) 
2.46 (1.85, 3.28) x103 1.75 (1.5, 2.1) x103 0.71 (0.51, 0.98) 0.040 
iAUCins 10-120 mins 
†
 
(pmol L-1 x min) 
48.1 (35.5, 65.2) x103  29.9 (23.3, 38.4) 
x103 
0.62 (0.42, 0.91) 0.017 
AUCISR over 120 mins  
(pmol m-2 BSA x min)   




(pmol m-2 BSA)/ (mmol L-1 
min-1) 




(pmol min-1 m2 BSA)/ 
(mmol L-1) 
49.8 (20.1)  47.1 (18.8) -2.67 (-14.4, 9.07) 0.649 
Average (endogenous) 
insulin clearance  
(mL m-2 BSA min-1) 
771.6 (227.8) 1381 (534.3) 609.5 (349.5, 869.6) <0.001 
MCRI 
(mL m-2 BSA min -1) 
482.8 (70.6) 530.7 (78.7)  47.9 (1.6, 94.3) 0.043 
Basal EGP 
(μmol kg -1 FFM min-1) 
4.69 (2.39) 4.04 (2.29) -0.65 (-2.13,0.83) 0.377 
% suppression EGP ‡
 
 





3.78 (1.13)  6.08 (5.04) 2.29 (0.06, 4.52) 0.044 
M value ‡ 
mg kg-1 FFM min−1 
9.65 (2.32) 9.51 (3.86) -0.14 (-2.08, 1.81) 0.89 
M/I ‡ 
(mg kg-1 FFM min−1)/ 
(pmol L-1) 
0.0171 (0.0059) 0.0189 (0.0094) 0.00184 (-0.0030, 
0.0066)  
0.44 
Data presented as mean (SD) or geometric mean (95% CI) for log transformed data (†). Differences between the 
two ethnic groups were determined using independent samples t-tests. Fating plasma glucose levels from 
hyperglycaemic clamp visit. ‡ Previously reported data [26] § Previously reported data [30] 
Abbreviations: BA, black African; BSA: Body surface area; EGP, Endogenous glucose production; FFM, Fat free 
mass. IHL, Intrahepatic lipid; WE, white European; iAUC, incremental area under the curve; AUC(ISR), area 







Figure 1a: Plasma insulin response by ethnic group during the hyperglycaemic clamp. BA = black 







Figure 1b: Plasma C-peptide response by ethnic group during the hyperglycaemic clamp.  BA 







Figure 2a: Associations between average insulin clearance and whole-body insulin 
sensitivity (M value) in white European (WE) and black African (BA) men. Data presented 
using the Pearson correlation coefficient: BA: r= 0.051, p=0.837; WE: r=0.691, p=0.001. 




Figure 2b: Associations between average insulin clearance and whole-body insulin 
sensitivity (M/I) in white European (WE) and black African (BA) men. Data presented using 
the Pearson correlation coefficient: BA: r= 0.179, p=0.464; WE: r=0.697, p<0.001. 






P interaction = 0.022 







Figure 2c: Associations between average insulin clearance and hepatic insulin sensitivity (% 
suppression EGP) in white European (WE) and black African (BA) men. Data presented 
using the Pearson correlation coefficient: BA: r= -0.169, p=0.488; WE: r=0.417, p=0.068. 






Figure 2d:  Associations between average endogenous insulin clearance (measured during 
hyperglycaemic clamp) and metabolic clearance rate of (exogenous) insulin (MCRI, 
measured during hyperinsulinaemic-euglycaemic clamp) in white European (WE) and black 
African (BA) men.  Data presented using the Pearson correlation coefficient: r=0.298, 




















P interaction = 0.057 





Figure 2e: Associations between average insulin clearance and intrahepatic lipid (IHL) in 
white European (WE) and black African (BA) men. Data presented using the Pearson 
correlation coefficient: BA: r= -0.134, p =0.584; WE: r= -0.674, p= 0.001. Interaction by 
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